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1607-551X/Copyright ª 2014, KaohsiuAbstract We investigated an optimal cutoff level of free/total PSA ratios (f/t PSA) in predict-
ing prostate cancer in different age groups, focusing on the avoidance of unnecessary prostate
biopsies. A total of 4955 men were enrolled into the study. Serum tPSA, fPSA, and f/t PSA
ratios were determined for the study population. All males who had suspicious digital rectal ex-
amination and tPSA > 4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy.
Receiver operating characteristic (ROC) curves for each group were generated by plotting the
sensitivity versus 1-specificity for the f/t PSA ratio. The sensitivity, specificity, positive likeli-
hood ratio (PLR), and negative likelihood ratio (NLR) were obtained using various f/t PSA ratio
cutoffs for different age groups. There were 657 patients with a PSA level of 4e10 ng/mL. Ac-
cording to sensitivity and specificity f/t% PSA cutoff points were determined to be 10%, 15%,
15%, and 10% in 50e59 years, 60e69 years, >70 years, and all ages categories, respectively, in
patients with initial PSA level of 4e10 ng/mL. f/t PSA ratio had an area under the curve (AUC)
value of 0.81 (95% confidence level: 0.80e0.82) for all age groups in detecting prostate cancer.eclare no conflicts of interest.
deniyet University, Goztepe Training and Research Hospital, Dr Erkin cad. Kadikoy/Istanbul, Turkey.
.com (B. Erol).
4.03.008
ng Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
546 B. Erol et al.f/t PSA ratio has an AUC value of 0.669 (0.632e0.705) in detecting prostate cancer among pa-
tients with a PSA level of 4e10 ng/mL. Ten percent of f/t PSA ratio had the highest specificity
with PLR and 30% f/t PSA ratio had the highest sensitivity with lower NLR in the all-age cate-
gories. The current study shows that the use of f/t PSA ratio in patients with PSA levels of 4
e10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnec-
essary biopsies. The age-related changes warrant further investigation in a large, multicentric,
and multinational population to improve the clinical use of f/t PSA cutoffs.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Serum prostate-specific antigen (PSA) is a useful biomarker
for screening of prostate cancer and monitoring patients for
disease progression [1,2]. Oesterling et al. [3] established
age-specific reference ranges for serum PSA levels to
improve its sensitivity in younger men and to increase its
specificity in older men [3]. However, recent findings
emphasize the limitation of these PSA threshold values to
discriminate between prostate cancer and benign disease
in asymptomatic men [4e6]. Since the identification of free
PSA (fPSA) by Stenman et al. [7], Lilja et al. [8], many
retrospective and prospective studies have shown the use-
fulness of the free/total (f/t) PSA ratio for differentiating
benign disease (BD) and prostate cancer in gray-zone pa-
tients who have PSA levels of 4e10 ng/mL in which BD and
cancers overlap. Despite the various cutoff levels defined in
different studies and our previous article for f/t PSA, the
cutoff levels for f/t PSA ratios specified for different age
groups have not yet been determined as tPSA [9e15].
The aim of this study was to evaluate the efficacy and
limitation of f/t PSA ratios in different age groups and to
determine cutoff levels for any age in a large scale. Some
controversy exists regarding the clinical benefits of f/t PSA
because the large overlap between prostate cancer and BD
for various f/t PSA cutoff levels provides conflicting data for
the correlation between f/t PSA and a pathologic outcome.Methods
The study population comprised 4955 subjects who under-
went PSA-based prostate cancer screening in our institu-
tion. Blood samples were drawn before any prostatic
manipulation after each patient provided informed con-
sent. tPSA and fPSA levels were measured in fasting pe-
ripheral blood samples. Serum PSA levels were analyzed by
immunometric assay (Immulite 2000, DPC, Los Angeles, CA,
USA) with analytical sensitivity of 0.04 ng/mL. Serum fPSA
levels were analyzed using a solid phase, two-site sequen-
tial chemiluminescent immunometric assay (Immulite 2000,
DPC) with analytical sensitivity of 0.02 ng/mL. The intra-
and interassay coefficients of variations (CVs) were below
5.0 % for total and free PSA.
Men age 40e80 years were included of the study.
Exclusion criteria were as follows: <40 years and >80
years, diagnosis of active urinary tract infection or other
systemic infection, acute and urinary retention. Alsoexcluded were patients who had underwent newly urethral
catheterization or cystoscopy.
All patients who had a suspicious digital rectal exami-
nation (DRE) and/or total PSA levels > 4 ng/mL underwent
transrectal ultrasonography (TRUS) and 12 core peripheral
zone biopsies were taken [16]. The samples were evaluated
by two pathologists to maintain consistency in the diagnosis
of prostate cancer. fPSA and tPSA levels were analyzed for
each sample. Serum tPSA, fPSA, and f/t PSA ratios were
determined for the study population.
Statistical analysis
Study data was analyzed in Medcalc 10.0 software (Chicago,
IL, USA). Continuous data were expressed as
mean  standard deviation or median, 95% confidence in-
terval (95% CI) was used if distribution was not normal, and
categorical data were presented as rates. Comparison of
two groups was performed by Mann-Whitney U test because
of abnormal distribution of fPSA and tPSA levels. The
Kolmogorov-Smirnov test was used to check the normal
distribution. Sensitivity, specificity, positive likelihood ratio
(PLR) and negative likelihood ratio was calculated by
receiving operating characteristic (ROC) curve analysis to
determine the diagnostic performance of f/t PSA ratios in
detecting prostate cancer. Values of area under the curve
(AUC) were also calculated by ROC analysis. All the hy-
potheses were constructed as two tailed and an a value of
0.05 was accepted as significant.
Results
A total of 4955 patients were enrolled into the study with a
mean age of 63.3  11.3 years. Prostate cancer was
detected in 109 patients (2.2%). There were no patients
<50 years of age in whom prostate cancer was diagnosed,
15 patients (13.7%) were aged between 50 years and 59
years, 38 patients (34.9%) were aged between 60 years and
69 years, and 56 patients (51.4%) were >70 years of age
(p < 0.001). Of 109 cancers, 7%, 53%, 36%, 2%, and 2% had a
Gleason score of 5, 6, 7, 8, and 9, respectively. In patients
with prostate cancer, 43%, 30%, 26%, and 1% had a clinical
stage T1c, T2a, T2b, and T3, respectively. Forty-four men
(40%) had undergone radical retropubic prostatectomy, 59
(54%) had received radiation therapy, and 6 (6%) had
received hormonal therapy.
The median fPSA levels for patients with prostate cancer
and benign histological findings were 1.36 ng/mL (95% CI:
Figure 1. Receiver operating characteristic curve of f/t
prostate-specific antigen (PSA) ratio for all age groups in 4955
patients.
Table 1 Sensitivity, specificity, and likelihood ratios of f/t prost
categories.
f/t PSA ratio 50e59 y
95% CI
f/t PSA 10%
Sensitivity 33.3 (12e62)
Specificity 95.5 (94e97)
PLR 7.3 (3.6e15)
NLR 0.7 (0.5e1.1)
f/t PSA 15%
Sensitivity 66.7 (38e88)
Specificity 85.4 (84e87)
PLR 4.6 (3.2e6.6)
NLR 0.39 (0.2e0.8)
f/t PSA 20%
Sensitivity 80 (52e95)
Specificity 71.2 (69e74)
PLR 2.8 (2.2e3.6)
NLR 0.28 (0.1e0.8)
f/t PSA 25%
Sensitivity 86.7 (60e98)
Specificity 52.4 (50e55)
PLR 1.8 (1.5e2.2)
NLR 0.25 (0.07e0.9)
f/t PSA 30%
Sensitivity 93.3 (68e99)
Specificity 36.9 (34e-39)
PLR 1.5 (1.3e1.7)
NLR 0.18 (0.03e1.2)
CI Z confidence interval; f/t Z free/total; NLR Z negative likelihoo
antigen.
f/t PSA ratio in a Turkish population 5471.1e1.6) and 0.34 ng/mL (95% CI: 0.33e0.35), respectively
(p < 0.0001). The median tPSA levels for patients with
prostate cancer and benign histological findings were
10.1 ng/mL (95% CI: 7.3e13.9) and 1.3 ng/mL (95% CI:
1.2e1.3), respectively (p < 0.0001). f/t PSA ratio had an
AUC value of 0.81 (95% CI: 0.80e0.82) for all age groups in
detecting prostate cancer. f/t PSA ratio of 10% had a
specificity of 95% (95% CI: 94e95) with a PLR of 7.6, and f/t
PSA ratio of 30% had a sensitivity of 91.7% (95% CI: 85e96)
with a NLR of 0.23 in all age groups. Fig. 1 displays the ROC
curve of f/t PSA ratio for all age groups in 4955 patients for
detecting prostate cancer.
Ten percent of f/t PSA ratio had the highest specificity
and PLR in the age categories; 50e59 years, 60e69 years,
and 70 years. Ten percent f/t PSA ratio had a specificity of
95.5% (95% CI: 94e97), 95.7% (95% CI: 94e97), 93.1% (95%
CI: 92e94), and PLR of 7.3 (3.6e15), 7.9 (5.1e12.2), and 6
(4.4e8.2) in age categories 50e59 years, 60e69 years, and
70 years, respectively (Table1). Thirty percent f/t PSA
ratio had the highest sensitivity with lower NLR in the all
age categories. Thirty percent f/t PSA ratio had a sensi-
tivity of 93.3% (95% CI: 68e99), 94.7% (95% CI: 82e99),
89.3% (95% CI: 78e96), and a NLR of 0.18 (95% CI:
0.03e1.2), 0.16 (95% CI: 0.04e0.6), and 0.31 (0.1e0.7) in
age categories 50e59 years, 60e69 years, and 70 years,
respectively. Table 1 displays the diagnostic performance
of f/t PSA ratios according to the age categories.ate-specific antigen ratios in all patients according to the age
60e69 y 70 y
34.2 (20e51) 41 (28e55)
95.7 (94e97) 93.1 (92e94)
7.9 (5.1e12.2) 6 (4.4e8.2)
0.69 (0.5e1) 0.63 (0.5e0.8)
63.2 (46e78) 69.6 (56e81)
83.1 (81e85) 81.7 (80e84)
3.8 (2.9e4.8) 3.8 (3.2e4.5)
0.44 (0.3e0.7) 0.37 (0.2e0.6)
79 (63e90) 78.6 (66e88)
66 (63e69) 66.5 (64e69)
2.3 (2e2.7) 2.4 (2e2.7)
0.32 (0.2e0.6) 0.32 (0.2e0.5)
89.5 (75e97) 85.7 (74e94)
46.8 (44e50) 48.9 (46e52)
1.7 (1.5e1.9) 1.7 (1.5e1.9)
0.23 (0.09e0.6) 0.29 (0.2e0.6)
94.7 (82e99) 89.3 (78e96)
32.7 (30e35) 34.2 (31.8e37)
1.4 (1.3e1.6) 1.4 (1.2e1.5)
0.16 (0.04e0.6) 0.31 (0.1e0.7)
d ratio; PLR Z positive likelihood ratio; PSA Z prostate-specific
Figure 2. Performance of f/t prostate-specific antigen (PSA)
ratio in 657 patients with a PSA level of 4e10 ng/mL.
548 B. Erol et al.There were 657 patients with a PSA level of 4e10 ng/mL.
Forty of these patients (6%) had received a diagnosis of
prostate cancer. f/t PSA ratio has an AUC value of 0.669
(0.632e0.705) in detecting prostate cancer among patientsTable 2 Sensitivity, specificity, and likelihood ratios of f/t prost
antigen level of 4e10 ng/mL according to the age categories.
f/t PSA ratio 50e59 y
95% CI
f/t PSA 10%
Sensitivity 41.6 (15e72)
Specificity 84.7 (76e91)
PLR 2.7 (1.4e5.3)
NLR 0.69 (0.4e1.3)
f/t PSA 15%
Sensitivity 75 (43e95)
Specificity 53 (43e63)
PLR 1.6 (1.1e2.3)
NLR 0.47 (0.2e1.3)
f/t PSA 20%
Sensitivity 83.3 (52e98)
Specificity 25.5 (17e35)
PLR 1.1 (0.7e1.7)
NLR 0.65 (0.2e2.3)
f/t PSA 25%
Sensitivity 91.7 (62e100)
Specificity 5.1 (1.7e12)
PLR 0.97 (0.4e2.3)
NLR 1.63 (0.2e10.7)
f/t PSA 30%
Sensitivity 100 (74e100)
Specificity 1 (0.03e5.6)
PLR 1 (0.1e7.1)
NLR 0
CI Z confidence interval; f/t Z free/total; NLR Z negative likelihoo
antigen.with a PSA level of 4e10 ng/mL. Fig. 2 displays the ROC
curve of f/t PSA ratio in patients with PSA level of 4e10 ng/
mL. Lower f/t PSA ratios had higher specificity and PLRs and
higher f/t PSA ratios were related to better sensitivity and
NLRs. Table 2 displays the performance of f/t PSA ratios in
age categories with a PSA level of 4e10 ng/mL.Discussion
PSA is one of the most important biomarkers for detecting
prostate cancer and guiding decisions to biopsies of the
prostate. Despite its adequate sensitivity, the use of PSA
testing is limited by a significant lack of specificity, which
can result in unnecessary biopsies. Use of the f/t PSA ratio
has been shown to improve specificity in detection of
prostate cancer. No definitive data are available indicating
the optimal %f/tPSA that should be applied.
Denham et al. [17] reported that the ratio f/t PSA holds
no benefit in discriminating between a patient with
prostate cancer and a patient with benign prostatic hiper-
plasia. In contrast to this report, previous studies and our
reports have demonstrated that at the PSA levels of
4.0e10.0 ng/mL, the ratio of f/t PSA significantly improves
discrimination between prostate cancer and benign condi-
tions and helps identify the need for prostate biopsy and
avoid unnecessary biopsies [15,17e22].ate-specific antigen ratios in patients with a prostate-specific
60e69 y 70 y
14.3 (2e43) 35.7 (13e65)
90.4 (85e94) 90.6 (87e93)
1.49 (0.4e5.4) 3.8 (1.9e7.7)
0.95 (0.6e1.5) 0.71 (0.4e1.2)
50 (23e77) 50 (23e77)
58.5 (51e66) 73.8 (69e79)
1.2 (0.7e2.1) 1.9 (1.1e3.2)
0.85 (0.5e1.5) 0.68 (0.4e1.2)
78.6 (49e95) 64.3 (35e87)
32.5 (26e40) 53.8 (48e60)
1.16 (0.8e1.6) 1.4 (0.9e2.1)
0.66 (0.2e1.8) 0.66 (0.3e1.4)
92.9 (66e100) 85.7 (57e98)
13.8 (9e20) 31.2 (26e37)
1.08 (0.7e1.6) 1.25 (1e1.6)
0.52 (008e3.4) 0.46 (0.1e1.7)
100 (77e100) 92.9 (66e100)
2.66 (0.9e6.1) 16.6 (13e21)
1.03 (0.4e2.4) 1.11 (0.8e1.5)
0 0.43 (0.07e2.9)
d ratio; PLR Z positive likelihood ratio; PSA Z prostate-specific
f/t PSA ratio in a Turkish population 549Partin et al. [23] suggested using f/t PSA ratio  15,
which would detect all advanced, nonorgan confined, and
large volume tumors, while avoiding 80% of biopsies in men
with insignificant disease, particularly in the intermediate
range of total PSA (4.1e10 ng/mL).
Catalona et al. [11] suggested a cutoff of 24% to detect
90% of cancers and to avoid 18% of benign biopsy findings in
patients with a PSA value 2.6e4.0 ng/mL. In an update,
Catalona et al. [18] examined a variety of cutoffs, some of
which were as low as 10%. Other investigators have rec-
ommended cutoffs of 18e27%. Chun et al. [24] demon-
strated that median f/t PSA ratio as most men had f/tPSA
values of >25% in Canadian men. Suzuki et al. [14] reported
that using a cancer probability cutoff level of 10% provides
a 26% reduction in the number of unnecessary biopsies
while maintaining a sensitivity of 90%. Their results are in
contrast to our findings and those of other studies [18e27].
In the current study, a 10% cutoff had a sensitivity of 37.6%
and specificity of 95% in all age groups. Table 2 shows an
increasing trend for specificity with decreasing f/t PSA ra-
tios in age categories of patients with tPSA of 4e10 ng/mL.
These results are correlated with those of Catalona et al.
[18] and other studies [19e22,25,26].
Age-specific reference rates have been proposed as a
means of improving specificity and positive predictive value
of the total PSA in screening for prostate cancer. Previous
studies demonstrated that the total PSA level is signifi-
cantly related to age; however, an age-specific f/t PSA ratio
has not yet been determinated. Chun et al. [24] hypothe-
sized that a relationship between f/tPSA ratio and age can
be established [24].
Age-specific cutoffs were also reported by Catalona
et al. [18] as 20%, 26%, and 28% f/t PSA ratios for ages
50e59 years, 60e69 years, and 70e75 years, respectively.
In the current study, the f/t% PSA cutoff points were
determined to be 10%, 15%, 15% and 10% in 50e59 years,
60e69 years, >70 years, and all ages categories, respec-
tively (Table 2). Ten percent f/t PSA ratio had the highest
specificity and PLR in the all age categories. Thirty percent
f/t PSA ratio had the highest sensitivity and a lower NLR in
the same age categories. These results are correlated with
our previous study [15]. However, the cutoff values deter-
mined in the current study display inconsistency with the
report by Catalona et al. [18]. A possible reason for the
different cutoff values could be the use of different assays.
In addition, this may be a result of using different statistical
approaches. Catalona et al. used high sensitivity as the
selection criterion for determining cutoff values. However,
sensitivity is a factor used to exclude the disease in the
clinical practice. In addition to sensitivity, we also recom-
mended the use of specificity and PLR for determining
cutoff values. The PLR predicts the posttest probability. A
high PLR avoids unnecessary biopsies and strongly predicts
disease in the gray zone.
Contradictory results in the aforementioned studies may
also be related to multiple variables, such as significant
degradation during frozen storage, study design, sample
size, cancer prevalence, assay differences, and many other
parameters, in addition to different statistical approaches
[27].
Our data are based almost entirely on Turkish men, not
accounting for racial variability. The omission of race maylimit the applicability of our findings. Our study has other
limitations; prostate volumes were not calculated. Several
authors have suggested that in patients with large pros-
tates, the determination of f/t PSA ratio lacks specificity in
discriminating prostate cancer and benign prostatic hy-
perplasia [28,29].
In conclusion, the current study shows that the use of f/t
PSA ratio in patients with PSA levels of 4e10 ng/mL should
enhance the specificity of PSA screening and decrease the
number of unnecessary biopsies. Ten percent f/t PSA ratio
had the highest specificity with PLR and 30% f/t PSA ratio
had the highest sensitivity and a lower NLR in the all age
categories. According to sensitivity and specificity, f/t% PSA
cutoff points were determined to be 10%, 15%, 15%, 10% in
age categories 50e59 years, 60e69 years, >70 years, and
all ages categories in patients with initial PSA level of
4e10 ng/mL. The choice of the best cutoff for the f/t PSA
ratio depends on a variety of arguments that mainly include
the combination of screening modalities used. The age-
related changes warrant further investigations in a larger,
multicentric and multinational population to improve the
clinical use of f/t PSA cutoffs.References
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